Akari Therapeutics Plc (AKTX): Going concern doubt
Severity scores the disclosed filing signal, not a judgment about the company or its securities.
What was disclosed
dequate funds are not available on a timely basis, we may be required to terminate or delay development for one or more of our product candidates, which raises substantial doubt about our ability to continue as a going concern.
Why it matters
A going-concern disclosure reflects substantial doubt about the company's ability to continue operating.